# Gracell Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gracell-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.gracellbio.com
- Total disclosed funding: $206M
- Latest round: Series C (Oct 29, 2020)
- Investors on record: 11

## About

Gracell Biotechnology Ltd. is a biopharmaceutical company focused on developing innovative cell therapies to combat cancer and autoimmune diseases.Founded in 2017 in Shanghai, China, Gracell Biotechnology Ltd. specializes in advanced cell therapies. The company has undergone strategic developments, including a significant transition to public ownership. Wei Cao serves as both Founder and CEO. Gracell successfully raised USD 1,000.00 mn in its latest funding round on January 7, 2021, participating in an IPO that sold 11 million shares at USD 19 per share. To date, the company has completed a total of 8 deals.Gracell develops innovative cell therapies addressing challenges in cancer and autoimmune diseases. Key offerings include the FasTCAR platform for rapid manufacturing of CAR-T cells, the TruUCART platform for off-the-shelf CAR-T therapies, and the SMART CART technology targeting solid tumors. The company markets its products primarily in North America and Europe to healthcare providers and research institutions.In 2021, Gracell reported revenue of USD 56,730.40, while the EBITDA for the year was USD -81,460,074.30. The revenue model focuses on B2B transactions through partnerships with healthcare institutions and pharmaceutical companies, with agreements that allow for the licensing and distribution of their therapies.Gracell Biotechnology Ltd. plans to launch new products and expand its market presence. Recent funding from the IPO will support these initiatives, including the advancement of the TruUCART platform. The company aims to broaden its reach into additional markets by targeting specific regions in North America and Europe, leveraging its innovative therapies to enhance patient access by the end of 2023.

## Funding rounds

- Series C, Oct 29, 2020, $100M — OrbiMed Advisors, Temasek Holdings, Vivo Capital, Wellington Management, Lilly Asia Ventures, 5Y Capital, King Star Capital
- Series B, Feb 25, 2019, $85M — Temasek Holdings, Lilly Asia Ventures, Kington Capital, King Star Capital
- Series B, Sep 21, 2018 — Lilly Asia Ventures, Suzhou Minying Capital Investment
- Series A, Nov 20, 2017, $11M — 6 Dimensions Capital
- Angel, Aug 15, 2017, $10M — Frontline BioVentures, 6 Dimensions Capital

## Investors

- Frontline BioVentures (https://capitalatlas.ai/funds/frontline-bioventures) — Angel
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Angel, Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- Suzhou Minying Capital Investment — Series B
- Temasek Holdings — Series B, Series C
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series B
- King Star Capital — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C